198 related articles for article (PubMed ID: 15569683)
1. Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein.
Takahashi H; Hatakeyama S; Saitoh H; Nakayama KI
J Biol Chem; 2005 Feb; 280(7):5611-21. PubMed ID: 15569683
[TBL] [Abstract][Full Text] [Related]
2. SUMO-1 regulates the conformational dynamics of thymine-DNA Glycosylase regulatory domain and competes with its DNA binding activity.
Smet-Nocca C; Wieruszeski JM; Léger H; Eilebrecht S; Benecke A
BMC Biochem; 2011 Feb; 12():4. PubMed ID: 21284855
[TBL] [Abstract][Full Text] [Related]
3. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
4. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
[TBL] [Abstract][Full Text] [Related]
5. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of thymine DNA glycosylase conjugated to SUMO-1.
Baba D; Maita N; Jee JG; Uchimura Y; Saitoh H; Sugasawa K; Hanaoka F; Tochio H; Hiroaki H; Shirakawa M
Nature; 2005 Jun; 435(7044):979-82. PubMed ID: 15959518
[TBL] [Abstract][Full Text] [Related]
8. The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML.
Engelhardt OG; Boutell C; Orr A; Ullrich E; Haller O; Everett RD
Exp Cell Res; 2003 Feb; 283(1):36-50. PubMed ID: 12565818
[TBL] [Abstract][Full Text] [Related]
9. E2-mediated small ubiquitin-like modifier (SUMO) modification of thymine DNA glycosylase is efficient but not selective for the enzyme-product complex.
Coey CT; Fitzgerald ME; Maiti A; Reiter KH; Guzzo CM; Matunis MJ; Drohat AC
J Biol Chem; 2014 May; 289(22):15810-9. PubMed ID: 24753249
[TBL] [Abstract][Full Text] [Related]
10. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
11. The promyelocytic leukemia protein stimulates SUMO conjugation in yeast.
Quimby BB; Yong-Gonzalez V; Anan T; Strunnikov AV; Dasso M
Oncogene; 2006 May; 25(21):2999-3005. PubMed ID: 16501610
[TBL] [Abstract][Full Text] [Related]
12. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
Fasci D; Anania VG; Lill JR; Salvesen GS
Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
[TBL] [Abstract][Full Text] [Related]
13. Interferon-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies.
Engelhardt OG; Ullrich E; Kochs G; Haller O
Exp Cell Res; 2001 Dec; 271(2):286-95. PubMed ID: 11716541
[TBL] [Abstract][Full Text] [Related]
14. ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator.
Karvonen U; Jääskeläinen T; Rytinki M; Kaikkonen S; Palvimo JJ
J Mol Biol; 2008 Oct; 382(3):585-600. PubMed ID: 18656483
[TBL] [Abstract][Full Text] [Related]
15. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
Janssen K; Hofmann TG; Jans DA; Hay RT; Schulze-Osthoff K; Fischer U
Oncogene; 2007 Mar; 26(11):1557-66. PubMed ID: 16924230
[TBL] [Abstract][Full Text] [Related]
16. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation.
Duprez E; Saurin AJ; Desterro JM; Lallemand-Breitenbach V; Howe K; Boddy MN; Solomon E; de Thé H; Hay RT; Freemont PS
J Cell Sci; 1999 Feb; 112 ( Pt 3)():381-93. PubMed ID: 9885291
[TBL] [Abstract][Full Text] [Related]
17. Serum response factor is modulated by the SUMO-1 conjugation system.
Matsuzaki K; Minami T; Tojo M; Honda Y; Uchimura Y; Saitoh H; Yasuda H; Nagahiro S; Saya H; Nakao M
Biochem Biophys Res Commun; 2003 Jun; 306(1):32-8. PubMed ID: 12788062
[TBL] [Abstract][Full Text] [Related]
18. Sumoylation of internally initiated Sp3 isoforms regulates transcriptional repression via a Trichostatin A-insensitive mechanism.
Spengler ML; Kennett SB; Moorefield KS; Simmons SO; Brattain MG; Horowitz JM
Cell Signal; 2005 Feb; 17(2):153-66. PubMed ID: 15494207
[TBL] [Abstract][Full Text] [Related]
19. SUMO-1 promotes association of SNURF (RNF4) with PML nuclear bodies.
Häkli M; Karvonen U; Jänne OA; Palvimo JJ
Exp Cell Res; 2005 Mar; 304(1):224-33. PubMed ID: 15707587
[TBL] [Abstract][Full Text] [Related]
20. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1.
Sternsdorf T; Jensen K; Will H
J Cell Biol; 1997 Dec; 139(7):1621-34. PubMed ID: 9412458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
